Chantal Burnison is COO of BCS Pharma Corporation a subsidiary of the Singaporean conglomerate BCS Business Consulting Services Pte Ltd. Her path towards becoming COO and inventing one of the most medically endorsed and revolutionary cosmetic lines began when she attended UCLA at the age of 16. Intent on a career in academic medicine, she conducted research targeted for the pharmaceutical industry parallel to her university neuro and biochemistry studies. Observing his daughter to be of inventor profile, her father, the inventor of the pneumatic air nail gun, persuaded Chantal to divert from a profession in medicine to that of law and the pharmaceutical industry. With his financial backing, and after receiving her doctorate in law, Chantal Burnison pursued the research, development, patent acquisition and FDA approvals of several of her medically published breakthrough compounds, including her designed class ( X-Andron) of novel, safe and efficacious nonsteroidal anti-androgens (Cyoctol and Ethocyn).
The anti-androgen molecular structures modulate intercellular DHT receptor binding. After years of safety and efficacy testing worldwide, the Cyoctol compounds are in their Phase II and III Clinical Trials, to date proving to safely and effectively treat numerous DHT mediated medical disorders, including acne vulgaris, hirsuitism, androgenetic alopecia, keloid scars ; and the Ethocyn compounds are confirmed (p<.001) to increase one’s important skin fibroblast cells’ elastin production in men and women over 25 years of age.